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LETTER
TO THE EDITOR
Dear Editor,We would like to thank Bellan and 
colleagues for their interest in our recent 
article regarding polymyalgia rheumatica 
(PMR) and paraneoplastic syndrome (1, 
2). We agree with the points they raise and 
are grateful for the aspects they highlight 
regarding the need for further research 
into PMR.
First, we agree that the definition of para-
neoplastic syndrome is controversial, as 
indeed is the definition of PMR. With no 
clear diagnostic test for PMR, and clas-
sification criteria (3) developed for use in 
trials rather than clinical practice, there 
is undoubtedly some heterogeneity in 
what is diagnosed as PMR. This is likely 
amplified by the comparison of samples 
recruited in different settings [e.g. ter-
tiary care (4), primary care (5)]. Further-
more, Bellan and colleagues (2) high-
light the related point of our exclusion 
of existing cancer in our previous study 
(5). Whilst we may accept that if PMR 
were a paraneoplastic syndrome, it does 
not need to occur before the malignancy 
is diagnosed, British guidelines for the 
diagnosis of PMR state that malignancy 
is an important differential diagnosis of 
polymyalgia symptoms and hence should 
be excluded as the cause of symptoms 
before a diagnosis of PMR is made. 
Given that clinicians may then undertake 
additional investigations (e.g. chest X-
ray, prostate specific antigen) to look for 
malignancy (and exclude this) in patients 
with PMR, this leads to additional risks 
of surveillance bias and hence our deci-
sion to exclude pre-existing cancer in our 
earlier study. Again, this makes answer-
ing the question as to whether PMR is a 
paraneoplastic syndrome or a differential 
diagnosis of malignancy problematic.
Second, the issue of the length of follow-up 
required is interesting. It is likely that stud-
ies based in routinely collected data have 
less detail than those for which data were 
collected specifically for research. How-
ever, they are likely to contain major diag-
noses, such as cancer, and in many cases, 
they are likely to have a longer follow-up, 
which may have the effect of increasing 
the likelihood of a later diagnosis of malig-
nancy being recorded during period under 
study. However, this may also mean that 
any short-term association with cancer is 
diluted by a lower risk of malignancy in 
the longer term. Indeed, the two studies in 
our review that specifically looked at inter-
vals of time from PMR diagnosis showed 
an initial increase in the risk of malignancy, 
followed by a return to normal risk (5, 6).
Finally, we agree that a specific cohort 
study may well be the only way to defini-
tively answer the question as to whether 
PMR is a truly paraneoplastic condition. 
However, this would still require clearly 
agreed definitions of both PMR and para-
neoplastic syndrome. Furthermore, our 
experience of recruiting a representative, 
prospective PMR cohort in England sug-
gests that whilst this is possible, it is not 
easy (7, 8).
Undoubtedly whether or not PMR is 
considered truly paraneoplastic requires 
further study, however the temporal re-
lationship with malignancy, whether as a 
differential diagnosis of PMR itself or as 
a paraneoplastic phenomenon, supports 
the need for physicians to actively con-
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sider (and screen for) malignancy, as per 
UK guidelines. We agree that only with 
prospectively conducted, long term cohort 
studies will we be able to accurately quan-
tify the risks of malignancy and determine 
whether certain subgroups of patients are at 
particularly high risk of cancer or whether 
this approach is required for all.
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